



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

Publication ID:

GBI0817005

Publication Date:

August 01, 2017

Pages:

132

Publisher:

GBI Research

Region:

Global [1]

\$4,995.00

Publication License Type *

Single User License (PDF), \$4,995.00

Site License (PDF), \$9,990.00

Global License (PDF), \$14,985.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

Summary

Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.

The patents protecting the three most commercially successful products, all marketed in wet AMD, are expected to expire in the coming years - Lucentis (ranibizumab) and Avastin (Bevacizumab) in 2018, and Eylea (aflibercept) in 2020. However, revenue from anticipated new approvals such as lampalizumab in dry AMD, Fovista (pegpleranib sodium) in wet AMD and brolucizumab in wet AMD and DME is expected to exceed the revenue lost following the patent expiry of current market leaders.

There is also significant interest in developing products for other indications; in 2017, Spark Therapeutics is expected to gain FDA approval in retinitis pigmentosa and Leber congenital amaurosis for its orphan drug, Voretigene Neparvovec, which if successful will be the first gene therapy approved for any genetic disease.

At the same time, a number of small and specialized ophthalmology companies such as Santen and Aerie are expected to enter the market, diversifying the landscape, which currently consists primarily of large biotech companies.

Scope

- The ophthalmology therapeutics market is forecast to reach \$35 billion in 2023. What are the key market segments driving this growth?
- The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late-stage products?
- Despite specific drug classes such as angiogenesis inhibitors dominating the commercial landscape, there is a very high proportion of novel drug classes in the pipeline. Which drug classes account for the largest proportion of early-stage development, and how do clinical failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
- Although they are dominant in the market, large biotech companies are anticipated to lose market share to specialty ophthalmology companies, which are much more active in the pipeline. Which of

the leading companies will have the highest market share by 2023? Which new companies will enter the market?

- What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the ophthalmology therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include glaucoma, AMD, DME, DR and DES.

- Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.

- Analyze the ophthalmology therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at ophthalmology therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.

- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.

- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.

- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from ophthalmology therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the disease area's key companies.

- Assess the licensing and co-development deal landscape for ophthalmology therapies.

Table Of Contents:

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 9

2.1 Therapy Area Introduction 9

2.1.1 Glaucoma 9

2.1.2 Age-Related Macular Degeneration 10

2.1.3 Diabetic Retinopathy 10

2.1.4 Diabetic Macular Edema 10

2.1.5 Dry Eye Syndrome 11

2.2 Symptoms 11

2.3	Diagnosis	13
2.4	Etiology and Pathophysiology	13
2.4.1	Etiology	13
2.4.2	Pathophysiology	15
2.5	Co-morbidities and Complications	18
2.6	Prognosis	19
2.6.1	Glaucoma	19
2.6.2	Age-Related Macular Degeneration	20
2.6.3	Diabetic Retinopathy and Diabetic Macular Edema	20
2.6.4	Dry Eye Syndrome	20
2.7	Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates	21
2.7.1	Glaucoma	21
2.7.2	Age-Related Macular Degeneration	22
2.7.3	Diabetic Macular Edema	23
2.7.4	Diabetic Retinopathy	24
2.7.5	Dry Eye Syndrome	25
2.8	Treatment	26
3	Key Marketed Products	29
3.1	Overview	29
3.2	Lucentis (ranibizumab)	29
3.3	Eylea (aflibercept)	30
3.4	Avastin (bevacizumab)	32
3.5	Restasis (cyclosporine)	33
3.6	Alphagan (brimonidine tartrate)	35
3.7	Lumigan (bimatoprost)	36
3.8	Xalatan (latanoprost)	37
3.9	Conclusion	38
4	Pipeline Landscape Assessment	39
4.1	Overview	39
4.2	Pipeline Development Landscape	39
4.3	Molecular Targets in the Pipeline	41
4.4	Clinical Trials	43
4.4.1	Failure Rate	43
4.4.2	Clinical Trial Duration	47
4.4.3	Clinical Trial Size	51
4.4.4	Aggregate Clinical Program Size	54
4.4.5	Assessment of Key Pipeline Products	58
4.4.6	Conclusion	64
5	Multi-Scenario Market Forecast to 2023	65

5.1 Overall Market Size	65
5.2 Generic Penetration	69
5.2.1 Angiogenesis Inhibitors (VEGF/PIGF/PDGF Inhibitors)	70
5.2.2 Antihistamines (Histamine H1 Receptor)	71
5.2.3 Anti-inflammatory Agents (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor)	71
5.2.4 IOP Modulators (Prostaglandins, Beta Blockers and the Rho Kinase Signaling Pathway)	72
6 Company Analysis and Positioning	74
6.1 Revenue and Market Share Analysis by Company	75
6.1.1 Novartis - Can the Approval of Fovista and Brolucizumab Offset Revenue Lost Following Patent Expirations?	79
6.1.2 Regeneron - Will Regeneron be Able to Retain its Position in the Ophthalmology Market across the Forecast Period with Eylea Alone?	81
6.1.3 Roche - To What Extent Will Pipeline Product Approvals Offset the Patent Expiries of Lucentis and Avastin?	83
6.1.4 Bayer - Can Bayer Retain its Position in the Ophthalmology Market Given its Small Product Portfolio and Ophthalmology Pipeline?	85
6.1.5 Allergan - How Will Declining Revenue from Restasis Affect Allergan's Overall Position within the Ophthalmology Therapy Area?	86
6.1.6 Shire - How Will Anticipated New Approvals Perform Across the Forecast Period?	87
6.1.7 Mallinckrodt - Will its Small Ophthalmology Portfolio and Limited Pipeline be Sufficient to Maintain the Position of Mallinckrodt in the Market?	88
6.1.8 Santen - Will Santen Continue to Rely on Ophthalmology Therapy Area for the Majority of its Company Revenue?	89
6.1.9 Aerie - Will Aerie be Able to Successfully Enter the Market with Two New Approvals?	91
6.2 Company Landscape	92
6.3 Marketed and Pipeline Portfolio Analysis	93
7 Strategic Consolidations	95
7.1 Licensing Deals	95
7.1.1 Deals by Region, Year and Value	95
7.1.2 Deals by Stage of Development and Value	97
7.1.3 Deals by Molecule Type, Mechanism of Action and Value	98
7.1.4 Table for Licensing Deals Valued Above \$100m	100
7.2 Co-development Deals	106
7.2.1 Deals by Region, Year and Value	106
7.2.2 Deals by Stage of Development and Value	107
7.2.3 Deals by Molecule Type, Mechanism of Action and Value	108
7.2.4 Table for Co-development Deals Valued Above \$100m	110
8 Appendix	113
8.1 References	113
8.2 Figures of All Clinical Stage Pipeline Products	121

8.3 Abbreviations	129
8.4 Disease List	130
8.5 Methodology	130
8.5.1 Coverage	130
8.5.2 Secondary Research	130
8.5.3 Market Size and Revenue Forecasts	131
8.5.4 Pipeline Analysis	131
8.5.5 Competitive Landscape	132
8.6 Contact Us	132
8.7 Disclaimer	132

List of Tables

1.1 List of Tables

Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES	12
Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES	14
Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES	19
Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2017	21
Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma	27
Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2017	29
Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2017	31
Table 8: Ophthalmology Therapeutics Market, Global, Off-label Indications for Avastin, 2016	32
Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2017	34
Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2017	35
Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2017	36
Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2017	37
Table 13: Ophthalmology, Global, Annual Revenue Forecast for Key Products (\$bn), 2016-2023	66
Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023	75
Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above \$100m, 2006-2017	100
Table 16: Ophthalmology Therapeutics Market, Global, Co-development Deals Valued Above \$100m, 2006-2017	110

List of Figures

1.2 List of Figures

Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2016-2023	22
Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2016-2023	23

Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2016-2023 24

Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2016-2023 25

Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2016-2023 26

Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis (\$bn), 2006-2023 30

Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea (\$bn), 2011-2023 32

Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin (\$bn), 2006-2023 33

Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis (\$bn), 2006-2023 35

Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan (\$bn), 2006-2023 36

Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan (\$bn), 2006-2023 37

Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan (\$m), 2006-2023 38

Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 39

Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2017 40

Figure 15: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2017 41

Figure 16: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2017 42

Figure 17: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2017 43

Figure 18: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017 44

Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017 45

Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017 46

Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017 47

Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 48

Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 49

Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017 50

Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 51

Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 52

Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 52

Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 53

Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 54

Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2017 55

Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 56

Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017 57

Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Mechanism of Action (participants), 2006-2017 58

Figure 34: Ophthalmology, Global, Revenue Forecast for Lampalizumab (\$m), 2018-2023 59

Figure 35: Ophthalmology, Global, Revenue Forecast for Fovista (\$m), 2017-2023 60

Figure 36: Ophthalmology, Global, Revenue Forecast for Brolucizumab (\$m), 2017-2023 61

Figure 37: Ophthalmology, Global, Revenue Forecast for Voretigene Neparvovec (\$m), 2017-2023 62

Figure 38: Ophthalmology, Global, Revenue Forecast for Roclatan (\$m), 2018-2023 63

Figure 39: Ophthalmology, Global, Revenue Forecast for Abicipar Pegol (\$m), 2020-2023 64

Figure 40: Ophthalmology, Global, Market Size (\$bn), 2016-2023 65

Figure 41: Ophthalmology, Global, Market Share of Key Products, 2016-2023 68

Figure 42: Ophthalmology, Global, Annual Revenue Forecast for Key Products (\$m), 2016-2023 69

Figure 43: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors (\$bn), 2016-2023 70

Figure 44: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines (\$m), 2016-2023 71

Figure 45: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories (\$m), 2016-2023 72

Figure 46: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs (\$bn), 2016-2023 73

Figure 47: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023 74

Figure 48: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023 77

Figure 49: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 78

Figure 50: Ophthalmology, Global, Revenues by Product Type, 2014-2022 79

Figure 51: Ophthalmology, Global, Novartis Annual Revenue Forecast (\$m), 2016-2023 80

Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast (\$m), 2016-2023 82

Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast (\$m), 2016-2023 84

Figure 54: Ophthalmology, Global, Bayer Annual Revenue Forecast (\$m), 2016-2023 85

Figure 55: Ophthalmology, Global, Allergan Annual Revenue Forecast (\$m), 2016-2023 87

Figure 56: Ophthalmology, Global, Shire Therapeutics Annual Revenue Forecast (\$m), 2016-2023 88

Figure 57: Ophthalmology, Global, Mallinckrodt Therapeutics Annual Revenue Forecast (\$m), 2016-2023 89

Figure 58: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast (\$m), 2016-2023 90

Figure 59: Ophthalmology, Global, Aerie Annual Revenue Forecast (\$m), 2016-2023 91

Figure 60: Ophthalmology, Global, Companies by Type, 2017 92

Figure 61: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2017 93

Figure 62: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2016-2023 94

Figure 63: Ophthalmology, Global, Licensing Deals, 2006-2017 96

Figure 64: Ophthalmology Global, Licensing Deals by Indication and Value, 2006-2017 97

Figure 65: Ophthalmology, Global, Licensing Deals, 2006-2017 98

Figure 66: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017 99

Figure 67: Ophthalmology, Global, Co-development Deals, 2006-2017 107

Figure 68: Ophthalmology, Global, Co-development Deals, 2006-2017 108

Figure 69: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017 109

Figure 70: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1 121

Figure 71: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 2 122

Figure 72: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 3 123

Figure 73: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 4 124

Figure 74: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 5 125

Figure 75: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 6 126

Figure 76: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 7 127

Figure 77: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 8 128

Figure 78: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 9 129

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.

- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/gbi-research/global-ophthalmology-drugs-market-2023-angiogenesis-inhibitors-wamd-set-retain-high>

Links

[1] <https://www.drugpipeline.net/region/global>